Combiplex Lipid Injection

Adult dosage

This drug is administered via central venous route. The adult dosage is 0.16 g to 0.35 g of nitrogen per kg of body weight per day (1 g to 2 g of amino acids per kg of body weight per day). The maximum daily dosage is 36 mL per kg of body weight, equating to 1.44 g of amino acids, 5.76 g of glucose, and 1.44 g of fat per kg of body weight. Required caloric intake is 25

Children's dosage

The pediatric dosage is 0.35 g to 0.45 g of nitrogen per kg of body weight per day (2 g to 3 g of amino acids per kg of body weight per day). Dosing should be adjusted based on the child's age, nutritional status, and medical condition.

This drug must be used under the direction of a physician. Caution is needed when administering this drug with calcium-containing medications intravenously. Specifically, mixing with Ceftriaxone can cause precipitation, so it should not be administered simultaneously using the same infusion device. If the same infusion line must be used, it should be thoroughly cleansed before and after the infusion. Premature infants or low-weight infants may not be able to adequately metabolize the lipid components of this drug, which can lead to elevated free fatty acid levels in the blood. Cases of death have been reported in premature infants with severe respiratory disorders when administered, so extreme caution is necessary. This drug should not be administered to certain patients. For example, patients with allergies to any components of this drug, those with abnormally high serum electrolyte concentrations, patients with severely impaired kidney or liver function, those with congenital amino acid metabolism disorders, metabolic acidosis or lactic acidosis, adrenal insufficiency, pulmonary edema or heart failure, severe sepsis or lipid metabolism disorders, severely coagulation-disordered patients, myocardial infarction patients, infants under 2 years of age, and those sensitive to soybean oil, soy, or peanuts. Additionally, in patients with hyponatremia or high serum osmolality, care should be taken when administering this drug, especially in those with hyperlipidemia or diabetic dyslipidemia, pancreatitis, or other lipid metabolism issues. Administering this drug in high doses or too rapidly can lead to adverse effects. During administration, acute reactions such as elevated body temperature, sweating, chills, headache, or respiratory distress can occasionally occur, and if these symptoms arise, administration must be stopped immediately. Prolonged administration may temporarily raise liver function test values and can rarely lead to hepatomegaly or jaundice and thrombocytopenia. When used in children, caloric, amino acid, electrolyte, and fluid requirements must be individually adjusted, and the patient's condition should be closely monitored during intravenous administration. During central venous administration, there is a risk of infection, so strict aseptic conditions must be maintained, and administering hypertonic solutions in peripheral veins may cause venous irritation. Regular checks of blood glucose, electrolytes, fluid balance, acid-base balance, liver function, and blood counts should be conducted during administration, and if hyperglycemia occurs, administration speed may need to be adjusted or insulin therapy might be required. Serum triglyceride levels must be periodically checked and managed to avoid exceeding normal values; daily tests should be conducted if lipid metabolism disorders are suspected. When mixing with other drugs, compatibility must be verified, and it is essential not to use the same infusion equipment if administered concurrently with blood, as agglutination reactions can occur. The safety of this drug in pregnant or nursing women has not been established, and it should only be administered when the benefits of treatment outweigh the risks. For newborns, infants, and children, it is recommended to use pediatric amino acid preparations to meet specific metabolic needs. Elderly patients may have reduced bodily functions, so careful adjustment of administration speed and dosage is necessary. In cases of overdose, symptoms of acidosis, fluid overload, hyperglycemia, vomiting, chills, liver dysfunction, hyperlipidemia, and others may arise. Administration must be stopped immediately, and treatment such as dialysis may be necessary. Finally, precautions should be taken during administration to ensure no air enters the container to prevent air embolism, and continuous connections should be avoided.

Serious side effects

• Respiratory distress, fever, skin rash, and anaphylactic reactions such as respiratory distress
• Hepatomegaly and jaundice (very rarely) observed

Mild side effects

• Fever
• sweating
• chills
• headache
• thrombocytopenia
• elevated ALP
• transaminases
• bilirubin levels
• hepatomegaly
• hyperglycemia

This drug should be stored in a sealed container to avoid contact with air and must be kept from freezing. Additionally, it is recommended to store it in a cool place below 25 degrees to maintain its effectiveness.

Appearance

A transparent plastic bag for infusion containing three compartments separated by two membranes, filled with solutions A, B, and C. Solution A is a white emulsion, a fluid dosage form.

Package unit

1000 mL, 1450 mL